R Latini

Summary

Affiliation: Istituto di Ricerche Farmacologiche Mario Negri
Country: Italy

Publications

  1. ncbi Incremental prognostic value of changes in B-type natriuretic peptide in heart failure
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Am J Med 119:70.e23-30. 2006
  2. ncbi Anaesthesiological strategies in elective craniotomy: randomized, equivalence, open trial--the NeuroMorfeo trial
    Giuseppe Citerio
    Neuroanaesthesia and Neurointensive Care Unit, Department of Perioperative Medicine and Intensive Care, San Gerardo Hospital, Monza, Milano, Italy
    Trials 10:19. 2009
  3. ncbi The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Eur Heart J 25:292-9. 2004
  4. ncbi Valsartan for the treatment of heart failure
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche, Mario Negri, Via Eritrea 62, 20157 Milan, Italy
    Expert Opin Pharmacother 5:181-93. 2004
  5. ncbi Biomarkers of myocyte injury in heart failure
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Heart Fail Clin 5:529-36. 2009
  6. ncbi Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAMI) trial
    Roberto Latini
    Istituto Mario Negri, Milano, Italy
    Am Heart J 146:133. 2003
  7. ncbi Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction
    Roberto Latini
    Mario Negri Institute for Pharmacological Research, Milan, Italy
    Circulation 110:2349-54. 2004
  8. ncbi Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)
    Roberto Latini
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Circulation 106:2454-8. 2002
  9. ncbi Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure?
    Roberto Latini
    Department of Cardiovascular Research, Instituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, Milan 20156, Italy
    Heart Fail Rev 13:415-23. 2008
  10. ncbi Neurohormonal modulation in heart failure of ischemic etiology: correlates with left ventricular remodeling
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, 20157 Milan, Italy
    Curr Heart Fail Rep 3:157-63. 2006

Detail Information

Publications78

  1. ncbi Incremental prognostic value of changes in B-type natriuretic peptide in heart failure
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Am J Med 119:70.e23-30. 2006
    ..We hypothesized that B-type natriuretic peptide changes during treatment of heart failure may provide independent information on disease progression and outcome in patients enrolled in the Val-HeFT trial...
  2. ncbi Anaesthesiological strategies in elective craniotomy: randomized, equivalence, open trial--the NeuroMorfeo trial
    Giuseppe Citerio
    Neuroanaesthesia and Neurointensive Care Unit, Department of Perioperative Medicine and Intensive Care, San Gerardo Hospital, Monza, Milano, Italy
    Trials 10:19. 2009
    ..This trial, named NeuroMorfeo, aims to assess the equivalence between volatile and intravenous anaesthetics for neurosurgical procedures...
  3. ncbi The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Eur Heart J 25:292-9. 2004
    ..Mainly because of small sample size, the predictive value of different NH has never been compared, while taking into account demographic, clinical and echocardiographic markers of risk in HF...
  4. ncbi Valsartan for the treatment of heart failure
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche, Mario Negri, Via Eritrea 62, 20157 Milan, Italy
    Expert Opin Pharmacother 5:181-93. 2004
    ....
  5. ncbi Biomarkers of myocyte injury in heart failure
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Heart Fail Clin 5:529-36. 2009
    ..The advent of a new generation of high-sensitivity immunoassays for cardiac troponins offers challenges for scientists and clinicians and will likely change the understanding and interpretation of cardiac injury...
  6. ncbi Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAMI) trial
    Roberto Latini
    Istituto Mario Negri, Milano, Italy
    Am Heart J 146:133. 2003
    ....
  7. ncbi Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction
    Roberto Latini
    Mario Negri Institute for Pharmacological Research, Milan, Italy
    Circulation 110:2349-54. 2004
    ..The aim of this study was to assess the prognostic value of PTX3 in MI compared with the best-known and clinically relevant biological markers...
  8. ncbi Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)
    Roberto Latini
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Circulation 106:2454-8. 2002
    ..The long-term effects of angiotensin receptor blockers on BNP and NE in heart failure patients are not known...
  9. ncbi Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure?
    Roberto Latini
    Department of Cardiovascular Research, Instituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, Milan 20156, Italy
    Heart Fail Rev 13:415-23. 2008
    ..The evidences discussed herein provide a strong basis for the ongoing clinical trials testing EPO in chronic HF...
  10. ncbi Neurohormonal modulation in heart failure of ischemic etiology: correlates with left ventricular remodeling
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, 20157 Milan, Italy
    Curr Heart Fail Rep 3:157-63. 2006
    ..Whether knowledge of biomarkers' concentration can improve the clinical outcome of patients with HF by helping in guiding and monitoring their therapy treatment is a stimulating working hypothesis still to be verified...
  11. ncbi Cardiac protection by pharmacological modulation of inflammation
    R Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
    Expert Opin Investig Drugs 10:1913-24. 2001
    ..Similarly, results of trials aimed at preventing cardiovascular events by eradicating chronic infections will be among the first to directly test whether such therapies will decrease risks of cardiovascular disease...
  12. ncbi Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Circulation 116:1242-9. 2007
    ..We assessed the prognostic value of circulating cardiac troponin T in patients with stable chronic HF with a traditional (cTnT) and a new precommercial highly sensitive assay (hsTnT)...
  13. ncbi Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial
    R Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea, 62 20157 Milan, Italy
    Heart Dis 2:185-90. 2000
    ..Lisinopril is safe and effective when given early after the onset of myocardial infarction, regardless of a concomitant administration of ASA started early and continued over a 6-week period...
  14. ncbi Left ventricular response to beta-adrenergic stimulation in aging rats
    S Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Gerontol A Biol Sci Med Sci 55:B35-41; discussion B42-3. 2000
    ....
  15. ncbi Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat
    Noeleen De Angelis
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri Milan, Italy
    J Mol Cell Cardiol 34:1655-65. 2002
    ....
  16. ncbi Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial
    R Latini
    Istituto di Ricerche Farmacologiche Mario Negri, Milan Istituti Ospitalieri, Cremona POL Madonna della Consolazione, Reggio Calabria, Italy
    J Intern Med 269:160-71. 2011
    ..we evaluated the prognostic role of circulating cardiovascular biomarkers in patients with a history of recent atrial fibrillation (AF)...
  17. ncbi Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial
    Lidia Staszewsky
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Card Fail 13:797-804. 2007
    ..Because little information is available about the population of patients with both syndromes, we assessed the characteristics and the independent contribution of COPD to outcomes in patients with stable chronic heart failure...
  18. ncbi Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study
    G Zuanetti
    Istituto Mario Negri, Milano, Italy
    Circulation 96:4239-45. 1997
    ..We evaluated whether treatment with an ACE inhibitor begun within 24 hours from the onset of symptoms is able to decrease mortality and morbidity of diabetic patients with acute MI...
  19. ncbi Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting
    R Latini
    Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
    J Am Coll Cardiol 35:1801-7. 2000
    ..We sought to determine whether the clinical effects of early angiotensin-converting enzyme (ACE) inhibitor (ACEi) treatment for acute myocardial infarction (MI) are influenced by the concomitant use of aspirin (ASA)...
  20. ncbi Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Card Fail 8:288-99. 2002
    ..Development of rapid, accurate and affordable diagnostic methods will allow the routine monitoring of BNP in a wide spectrum of settings, from general practice to controlled clinical trials...
  21. ncbi The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT)
    Serge Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Card Fail 12:375-80. 2006
    ..In this setting, BNP remained the strongest neurohormonal prognostic factor...
  22. ncbi A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury
    Fabio Fiordaliso
    Mario Negri Institute for Pharmacological Research, Milan 20157, Italy
    Proc Natl Acad Sci U S A 102:2046-51. 2005
    ..Furthermore, these findings expand the activity spectrum of CEPO to tissues outside the nervous system...
  23. ncbi Disruption of the Ang II type 1 receptor promotes longevity in mice
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, Bergamo, Italy
    J Clin Invest 119:524-30. 2009
    ....
  24. ncbi Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data
    Serge Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Clin Chem 52:1528-38. 2006
    ..This work aimed to provide a direct comparison of the prognostic value of BNP and NT-proBNP in patients with chronic and stable HF...
  25. ncbi Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats
    Fabio Fiordaliso
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milan, Italy
    J Mol Cell Cardiol 37:959-68. 2004
    ..NAC effectively protects from hyperglycemia-induced myocyte cell death and compensatory hypertrophy through direct scavenging of ROS and replenishment of the intracellular glutathione content...
  26. ncbi Effect of beta-adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats
    Fabio Fiordaliso
    Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research, 20157 Milan, Italy
    Life Sci 81:951-9. 2007
    ..In conclusion, hypertensive rat is no more susceptible than its normotensive control to acute apoptosis induced by diabetes. Oxidative stress might be considered the common trigger for cardiac myocyte apoptosis in both conditions...
  27. ncbi Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes
    Fabio Fiordaliso
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milan, Italy
    Life Sci 79:121-9. 2006
    ..The absence of an additive effect, suggests a common mechanism of action, through the reduction of oxidative stress...
  28. ncbi An update on cardiac troponins as circulating biomarkers in heart failure
    Serge Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa 19, 20156, Milan, Italy
    Curr Heart Fail Rep 7:15-21. 2010
    ..In the absence of further experimental evidences, the pathophysiologic basis for the elevation of circulating cardiac troponins in patients with stable chronic heart failure remains speculative...
  29. ncbi Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure
    Serge Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Clin Chem Lab Med 40:761-3. 2002
    ..16 pM, ratio 24) and NT-proBNP (1306 vs. 57 pM, ratio 23). We conclude that N-terminal proBNP, as assayed in the present study, correlates equally to BNP with clinical variables in patients with heart failure...
  30. ncbi The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial
    Serge Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, Milan, Italy
    Eur J Heart Fail 12:338-47. 2010
    ..We measured the plasma concentrations of four stable precursor fragments of neurohormonal systems in patients with chronic HF and evaluated their relationship with outcome...
  31. ncbi Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)
    Serge Masson
    Department of Cardiovascular Reearch, Istituto Mario Negri, Milan, Italy
    J Am Coll Cardiol 52:997-1003. 2008
    ..This study sought to evaluate the association between changes over time of N-terminal pro-brain natriuretic peptide (NT-proBNP) expressed in different ways and outcome in patients with stable and chronic heart failure (HF)...
  32. ncbi Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial
    Serge Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Circ Heart Fail 3:65-72. 2010
    ..There is, however, only limited information on the prevalence and prognostic role of urinary albumin excretion in patients with established chronic heart failure...
  33. ncbi Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction
    Serge Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Card Fail 10:433-41. 2004
    ..CONCLUSION: In aged rats with small to moderate MI, eplerenone normalized diastolic relaxation, possibly through a reduction of interstitial fibrosis...
  34. ncbi CHF-1024, a DA2/alpha2 agonist, blunts norepinephrine excretion and cardiac fibrosis in pressure overload
    S Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmcologiche-Mario Negri, Milan, Italy
    Cardiovasc Drugs Ther 15:131-8. 2001
    ..The DA2/alpha2 agonist CHF-1024 effectively blunts adrenergic drive and cardiac fibrosis in a rat model of pressure overload...
  35. ncbi PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans
    G Peri
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Circulation 102:636-41. 2000
    ..The possibility that PTX3 is altered in patients with acute myocardial infarction (AMI) has not yet been tested...
  36. ncbi In vivo cardioprotection by N-acetylcysteine and isosorbide 5-mononitrate in a rat model of ischemia-reperfusion
    Laura Calvillo
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milano
    Cardiovasc Drugs Ther 17:199-208. 2003
    ....
  37. ncbi Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction
    Monica Salio
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Circulation 117:1055-64. 2008
    ..It was therefore important to assess whether PTX3 plays a pathogenetic role in acute myocardial infarction...
  38. ncbi Amino-terminal pro-B-type natriuretic peptides and prognosis in chronic heart failure
    Serge Masson
    Department of Cardiovascular Research, Laboratory of Cardiovascular Clinical Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Am J Cardiol 101:56-60. 2008
    ..Thus, serial assessment of NT-proBNP is valuable for prognostication in chronic HF in outpatients, and, as such, a measurement at each patient visit or the following of changes in clinical stability is recommended...
  39. ncbi Cardiac mesoangioblasts are committed, self-renewable progenitors, associated with small vessels of juvenile mouse ventricle
    B G Galvez
    Stem Cell Research Institute, San Raffaele Scientific Institute, Milan, Italy
    Cell Death Differ 15:1417-28. 2008
    ..These data identify cardiac mesoangioblasts as committed progenitors, downstream of earlier stem/progenitor cells and suitable for the cell therapy of a subset of juvenile cardiac diseases...
  40. ncbi The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers
    E Riva
    Istituto Ricerche Farmacologiche Mario Negri, Milan, Italy
    Br J Pharmacol 104:823-8. 1991
    ..Interestingly, labetalol is devoid of this effect; whether the combination of RR and SR enantiomers could be of clinical importance warrants further investigation...
  41. ncbi Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling
    Laura Calvillo
    Mario Negri Institute of Pharmacological Research, 20157 Milan, Italy
    Proc Natl Acad Sci U S A 100:4802-6. 2003
    ....
  42. ncbi The long pentraxin PTX3 in vascular pathology
    Alberto Mantovani
    Research Laboratory in Immunology and Inflammation, Istituto Clinico Humanitas Via Manzoni, 56, 20089 Rozzano, Milan, Italy
    Vascul Pharmacol 45:326-30. 2006
    ....
  43. ncbi Mesoangioblasts, vessel-associated multipotent stem cells, repair the infarcted heart by multiple cellular mechanisms: a comparison with bone marrow progenitors, fibroblasts, and endothelial cells
    Daniela Galli
    Stem Cell Research Institute, DIBIT, H. San Raffaele, Milan, Italy
    Arterioscler Thromb Vasc Biol 25:692-7. 2005
    ..CONCLUSIONS: Mabs appear as effective as BMPCs in reducing postinfarction LV dysfunction, likely through production of antiapoptotic and angiogenic factors...
  44. ncbi High-sensitivity cardiac troponin T for detection of subtle abnormalities of cardiac phenotype in a general population of elderly individuals
    S Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Intern Med 273:306-17. 2013
    ..To investigate the association between circulating cardiac biomarkers and minor abnormalities in cardiac phenotype [left ventricular (LV) mass and midwall fractional shortening (MFS)] in elderly individuals in a general population sample...
  45. ncbi Follow-up of CRT-ICD: implications for the use of remote follow-up systems. Data from the InSync ICD Italian Registry
    Maurizio Lunati
    Niguarda Hospital, Milan, Italy
    Pacing Clin Electrophysiol 31:38-46. 2008
    ..Launch of remote follow-up systems in Europe is currently underway. However, there is insufficient understanding of postimplant practices with respect to device follow-up, reprogramming of device features, and postshock clinic visits...
  46. ncbi Levels of circulating pro-angiogenic cells predict cardiovascular outcomes in patients with chronic heart failure
    Giovanna Balconi
    Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research, Milano, Italy
    J Card Fail 15:747-55. 2009
    ..A low level of PACs is associated with worse outcome in patients with coronary heart disease. However, little is known about PACs in heart failure (HF)...
  47. ncbi Myocardial infarction: animal models
    Stefano Chimenti
    Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research, Milan, Italy
    Methods Mol Med 98:217-26. 2004
    ..Moreover, this model allows testing of the protective effects of anti-inflammatory drugs in experimental myocardial infarction...
  48. ncbi Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure)
    Alessandro Boccanelli
    Department of Cardiology, San Giovanni Addolorata Hospital, Rome, Italy
    J Cardiovasc Med (Hagerstown) 8:683-91. 2007
    ..AREA IN-CHF was planned to investigate the effects of canrenone on progression of LV remodelling in mild HF...
  49. ncbi Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT
    Henry Krum
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Monash University, Melbourne, Australia
    Int J Cardiol 119:48-53. 2007
    ..To address this, we retrospectively analyzed the Valsartan Heart Failure Trial (Val-HeFT) database to determine outcomes in CHF patients according to statin use at baseline...
  50. ncbi Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study
    Maylene Wong
    VA Greater Los Angeles Healthcare System and University of California at, Los Angeles, California 90073, USA
    J Am Coll Cardiol 40:970-5. 2002
    ..The objective of the study was to evaluate the effect of an angiotensin receptor blocker on left ventricular (LV) structure and function when added to prescribed heart failure therapy...
  51. ncbi Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial
    Giovanni Pedrazzini
    Division of Cardiology, Fondazione Cardiocentro Ticino, Lugano, Switzerland
    Am Heart J 155:388-94. 2008
    ..Furthermore, the 5-year survival analysis of GISSI-3 patients is reported...
  52. ncbi A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction
    Jawdat Abdulla
    Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark
    Eur J Heart Fail 9:129-35. 2007
    ....
  53. ncbi Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice
    Aldo P Maggioni
    Italian Association of Hospital Cardiologists (ANMCO) Research Center, Florence, Italy
    J Card Fail 11:91-8. 2005
    ..This finding is consistent in 2 different clinical contexts, a controlled trial and a registry in clinical practice, in which patient characteristics and outcome are largely different...
  54. ncbi RAAS inhibitors in the cardiovascular continuum: what is still missing?
    Aldo P Maggioni
    ANMCO Research Center, Via La Marmora 34, 5021 Florence, Italy
    Cardiovasc Drugs Ther 18:311-20. 2004
    ..Examples of these points, particularly regarding the size of modern cardiovascular trials to have the power to show protective effects, are illustrated by Val-HeFT, LIFE, ELITE II, VALIANT, VALUE, CHARM and NAVIGATOR...
  55. ncbi Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data
    Maylene Wong
    Veterans Affairs Greater Los Angeles Healthcare System, and David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California 90073, USA
    J Am Coll Cardiol 43:2022-7. 2004
    ..The objective of this study was to test the hypothesis that the severity of left ventricular remodeling predicts the response to treatment and outcomes in chronic heart failure...
  56. ncbi Doppler-derived mitral deceleration time as a strong prognostic marker of left ventricular remodeling and survival after acute myocardial infarction: results of the GISSI-3 echo substudy
    Pier L Temporelli
    Fondazione Salvatore Maugeri, Istituto di Ricovero e Cura a Carattere Scientifico, Verona, Italy
    J Am Coll Cardiol 43:1646-53. 2004
    ..The goal of this study was to assess the impact of left ventricular (LV) diastolic filling on remodeling and survival after acute myocardial infarction (AMI)...
  57. ncbi Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, Minn 55455, USA
    Circulation 108:1306-9. 2003
    ..The Valsartan Heart Failure Trial (Val-HeFT) provided the first opportunity to examine the long-term effects of an angiotensin receptor blocker on plasma aldosterone levels in patients with NYHA class II through IV heart failure...
  58. ncbi Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)
    Inder S Anand
    VA Medical Center and University of Minnesota, Minneapolis, Minn 55417, USA
    Circulation 107:1278-83. 2003
    ..We examined whether changes in brain natriuretic peptide (BNP) and norepinephrine (NE) over time are associated with corresponding changes in mortality and morbidity in the Valsartan Heart Failure Trial...
  59. ncbi The angiotensin-receptor blockers: from antihypertensives to cardiovascular all-round medications in 10 years?
    Aldo P Maggioni
    ANMCO, Research Center, Florence, Italy
    Blood Press 11:328-38. 2002
    ..A number of large-scale studies set to report within the next few years will further determine the effects of angiotensin-receptor blockers in a range of cardiovascular indications beyond hypertension...
  60. ncbi [Refractory heart failure. Antagonism of tumor necrosis factor alpha and endothelin in humans: 2 promises still to be honored]
    Marco Valgimigli
    Cattedra di Cardiologia, , Ferrara, e Centro di Fisiopatologia Cardiovascolare
    Ital Heart J Suppl 3:793-803. 2002
    ..The mechanisms by which TNF-alpha and ET might exert their negative biological actions are discussed together with an analysis of the possible reasons why they have failed so far in human CHF...
  61. ncbi Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors
    Aldo P Maggioni
    ANMCO Research Center, Florence, Italy
    J Am Coll Cardiol 40:1414-21. 2002
    ....
  62. ncbi Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review
    Koon K Teo
    Population Health Research Institute and Division of Cardiology, McMaster University, Ontario, Hamilton, Canada
    Lancet 360:1037-43. 2002
    ..We aimed to confirm or refute this theory...
  63. ncbi Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)
    Aldo P Maggioni
    ANMCO Research Center, Florence, Italy
    Am Heart J 149:548-57. 2005
    ..The aims of these subanalyses of Val-HeFT were to assess (a) the effects of valsartan in the prevention of AF, (b) the independent predictors of this event, and (c) the prognostic role of AF occurrence...
  64. ncbi Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val-HeFT)
    Maylene Wong
    VA Greater Los Angeles Healthcare System, 11301 Wilshire Blvd 500 6641, Los Angeles, CA 90073, USA
    J Am Soc Echocardiogr 15:293-301. 2002
    ..To qualify 302 multinational echocardiography sites to record and read serial studies and to monitor quality in 5010 patients randomized into Valsartan in Heart Failure Trial (Val-HeFT)...
  65. ncbi Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both
    Raymond T Yan
    The University Health Network, University of Toronto, Toronto, Ontario, Canada
    Am J Cardiol 96:698-704. 2005
    ..Serial measurements of these neurohormones may serve as useful surrogate markers of ventricular remodeling and prognosticators for clinical risk stratification...
  66. ncbi Signs and symptoms in chronic heart failure: relevance of clinical trial results to point of care-data from Val-HeFT
    Maylene Wong
    VA Greater Los Angeles Healthcare System and the David Geffen School of Medicine at UCLA, Los Angeles, USA
    Eur J Heart Fail 8:502-8. 2006
    ..Clinical trials emphasize mortality and morbidity endpoints...
  67. ncbi Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT
    Inder S Anand
    VA Medical Center, Minneapolis, MN 55417, USA
    Circulation 112:1121-7. 2005
    ..Anemia is known to be a prognostic marker for patients with heart failure. However, little is known about the prognostic value of changes in hemoglobin (Hgb) over time or about the causes of anemia...
  68. ncbi C-reactive protein in heart failure: prognostic value and the effect of valsartan
    Inder S Anand
    VA Medical Center, Minneapolis, MN 55417, USA
    Circulation 112:1428-34. 2005
    ..We assessed the prognostic value of CRP in patients randomized in Val-HeFT (Valsartan Heart Failure Trial) and studied changes in CRP that were associated with valsartan...
  69. ncbi Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence
    Marcello Disertori
    Department of Cardiology, S Chiara Hospital, Trento, Italy
    J Cardiovasc Med (Hagerstown) 7:29-38. 2006
    ..The GISSI-Atrial Fibrillation (AF) trial is a randomized, prospective, parallel group, placebo-controlled, multicentre study designed to test whether angiotensin II AT1-receptor blockers can reduce atrial fibrillation recurrence...
  70. ncbi [The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design]
    Giuseppe Cacciatore
    U O C di Cardiologia, Azienda Ospedaliera San Giovanni Addolorata, Roma
    Ital Heart J 6:66S-74S. 2005
    ..Therefore it seems interesting to evaluate the effect of canrenone, an aldosterone receptor blocker, on the progression of left ventricular dysfunction in patients with mild heart failure assuming standard therapy...
  71. ncbi [Recommendations for the clinical use of cardiac natriuretic peptides]
    Michele Emdin
    Istituto di Fisiologia Clinica del CNR, Pisa
    Ital Heart J Suppl 6:308-25. 2005
  72. ncbi Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor
    Michael Brines
    Kenneth S Warren Institute, Ossining, NY 10563, USA
    Proc Natl Acad Sci U S A 101:14907-12. 2004
    ..These data support the concept that EpoR and betacR comprise a tissue-protective heteroreceptor...
  73. ncbi Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial
    Mariantonietta Cicoira
    Department of Biomedical and Surgical Sciences, Section of Cardiology, University of Verona, Piazzale Stefani, 1 Verona, Italy, and Hospital General Universitari Vall D Hebron, Department of Cardiology, Barcelona, Spain
    Eur J Heart Fail 9:397-402. 2007
    ..To assess the relationship between body mass index (BMI), mortality and mode of death in chronic heart failure (CHF) patients; to define the shape of the relationship between BMI and mortality...
  74. ncbi Effects of exercise training on endothelial progenitor cells in patients with chronic heart failure
    Patrizio Sarto
    Department of Cardiology and Sports Medicine, Mirano Hospital, Mirano, Venice, Italy
    J Card Fail 13:701-8. 2007
    ....
  75. ncbi Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure
    Luigi Tavazzi
    Policlinico San Matteo, IRCCS, Pavia, Italy
    Eur J Heart Fail 6:635-41. 2004
    ....
  76. ncbi Comparison of brain natriuretic peptide plasma levels versus logistic EuroSCORE in predicting in-hospital and late postoperative mortality in patients undergoing aortic valve replacement for symptomatic aortic stenosis
    Giovanni Battista Pedrazzini
    Division of Cardiology, Cardiocentro Ticino, Lugano, Switzerland
    Am J Cardiol 102:749-54. 2008
    ..In conclusion, in symptomatic patients with severe AS, high preoperative BNP plasma level and high logES confirm their predicting value for short- and long-term outcome...
  77. ncbi Lung injury and recovery in a murine model of unilateral acid aspiration: functional, biochemical, and morphologic characterization
    Maria Amigoni
    Department of Experimental Medicine, University of Milano Bicocca and Department of Perioperative Medicine and Intensive Care, San Gerardo Hospital, Monza, Italy
    Anesthesiology 108:1037-46. 2008
    ..Most animal models developed to define its pathophysiology have focused on the acute (< or =24 h) phase of the injury. The authors describe a model of acid aspiration allowing the study of this type of lung injury over time...
  78. ncbi Recommendations for the clinical use of cardiac natriuretic peptides
    Michele Emdin
    Institute of Clinical Physiology, National Research Council, Pisa, Italy
    Ital Heart J 6:430-46. 2005